Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936335 · ClinicalTrials.gov registry record
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
A clinical trial of Atopic Dermatitis and Adverse Pregnancy Outcomes, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- 3,930
- Enrollment target
- 1
- Study location
NCT03936335: Recruiting study of Atopic Dermatitis and Adverse Pregnancy Outcomes, sponsored by Regeneron Pharmaceuticals.
NCT03936335 is a study of Atopic Dermatitis and Adverse Pregnancy Outcomes that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 3,930 participants, above the 583-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (574% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936335, a study of Atopic Dermatitis and Adverse Pregnancy Outcomes, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- 3,930 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Primary Outcome
Initially identified through the presence of corresponding codes on the insurance claims, confirmed through medical record review for infant outcomes: 01 April 2017 through December 2024
Conditions Studied
Interventions
- DRUG dupilumab
Study Locations (1)
Massachusetts
- Regeneron Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,930 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2027-01-21 |
What NCT03936335 shows while recruiting
NCT03936335 is an observational study that tracks outcomes without assigning an intervention. Its 3,930 participants enrollment target places it among the larger protocols in the corpus, above the 583-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (574% higher).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which dupilumab is the first listed.
NCT03936335 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03936335 about?
NCT03936335 is a clinical study titled "An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)". The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated wi...
What is the current status of trial NCT03936335?
This trial is currently recruiting. The enrollment target is 3,930 participants. The study started on 2019-09-30. Estimated completion is 2027-01-21.
What conditions does trial NCT03936335 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Adverse Pregnancy Outcomes.
What interventions are being tested in trial NCT03936335?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT03936335?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03936335 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03936335's enrollment target sits among peer trials
3,930 5th of 150 higher than 146 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI